ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > What's bringing us down ?

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Jul 20, 2021 2:47pm

75 Views

Post# 33576153

RE:RE:What's bringing us down ?

DKC, you say...

"Keep in mind, Biogen has Aducanumab and PMN has PMN310.

Any negative news for Aducanumab may be helping us in the long run. "

I'm not sure I agree with that. Aducanumab keeps the Amyloid Beta hypothesis alive and well, and that helps PMN310. We need medical practitioners to promote Aducanumab and stop the negativity despite limited and controversial efficacy data. They need to give it a chance, while the post-approval study is in the works. If not, FDA's approval will be withdrawn and that's that.

jmo
G1945V

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market